Company intelligence / Profile preview

K-STEMCELL

South Korea

Ownership: Private
Development stage: Commercial

Overview

K-STEMCELL develops and manufactures stem cell-based therapies for a range of indications including diabetes mellitus, orthopedic injuries (hip fractures), neurological injuries (spinal cord), cardiovascular/cerebrovascular diseases (ischemic events), and cancer. The company also produces stem cell-derived cosmetics and bio-safety products such as animal disinfectants. It has sought regulatory approval for processed cell production in Japan via its affiliate R-Japan. No detailed published clinical trial results were found in the provided sources.

Therapeutic areas: OncologyEndocrinologyOtherCardiovascularNeurology
Modalities: Stem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on K-STEMCELL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K-STEMCELL.

Explore the full profile